608
Participants
Start Date
February 11, 2016
Primary Completion Date
May 3, 2019
Study Completion Date
May 3, 2019
Ocrelizumab
Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
Ocrelizumab
Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Columbia University Medical Center, New York
South Shore Neurologic Associates P.C., Patchogue
Island Neurological Associates, P.C., Plainview
The MS Center of Northeastern New York, Latham
Jacobs Neurological Institute, Buffalo
Allegheny Neurological Associates, Pittsburgh
University of Maryland Medical Center; Department of Neurology, Baltimore
John Hopkins University School of Medicine, Baltimore
Ms Center Of Atlanta, Atlanta
Neurology Associates PA, Maitland
University of Miami Miller School of Medicine; Clinical Reseach Building, Miami
Infinity Clinical Research, LLC, Sunrise
Axiom Clinical Research of Florida, Tampa
University of South Florida - Bradenton, Tampa
Neurostudies Inc, Port Charlotte
North Central Neurology Associates, Cullman
Hope Neurology, Knoxville
Neurology Clinic PC, Cordova
Community Medical Associates Inc.; d.b.a. Norton Neurology Services MS Services, Louisville
Associates in Neurology PSC, Lexington
Neurology and Neuroscience Assoc., Inc., Westerville
The Ohio State University Wexner Medical Center; Department of Neurology, Columbus
Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40, Cleveland
UC Health Clinical Trials Office, Cincinnati
Neurology Specialists, Inc, Dayton
American Health Network Institute, LLC, Avon
Josephson Wallack Munshower Neurology PC, Indianapolis
Wayne State University; Department of Neurology, Detroit
Minneapolis Clinic of Neurology, Golden Valley
Consultants in Neurology Ltd, Northbrook
University of Chicago Hospital, Chicago
Washington University School of Medicine; Department of Neurology, St Louis
University of Kansas Medical Center; Division of Nuclear Medicine, Kansas City
Ochsner Clinic Foundation, New Orleans
Oklahoma Medical Research Foundation, Oklahoma City
Uni of Texas Health Science Center At Houston, Houston
Neurology Center of San Antonio, San Antonio
Central Texas Neurology Consultants, Round Rock
Bhupesh Dihenia M.D. P.A., Lubbock
IMMUNOe Research Centers, Centennial
Colorado Neurological Institute, Englewood
Advanced Neurology of Colorado, LLC, Fort Collins
Mountain Neurological Research Center; Roaring Fork Neurologt, P.C., Basalt
Rocky Mountain MS Clinic, Salt Lake City
Phoenix Neurological Associates Ltd, Phoenix
Barrow Neurological Institute, Phoenix
Territory Neurology and Research Institute, Tucson
Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance
The Research Center of Southern California, LLC, Carlsbad
Scripps Health, La Jolla
Fullerton Neurology and Headache Center, Fullerton
Mercy Medical Group; MS Centre Nurse, Carmichael
Providence Multiple Sclerosis Center, Portland
Swedish Neuroscience Institute, Seattle
MultiCare Health System Institute for Research and Innovation, Tacoma
UCSF- Multiple Sclerosis Centre; Department of Neurology, San Francisco
Associated Neurologists of Southern CT PC, Fairfield
KI Health Partners, LLC; New England Institute for Clinical Research, Stamford
Lahey Clinic Med Ctr, Lexington
Massachusetts General Hospital, Boston
Beth Israel Deaconess Med Ctr; Neurology/MS Center, Boston
Dragonfly Research, LLC, Wellesley
UMASS Memorial Medical Center, Worcester
Rutgers New Jersey Medical School, Newark
Holy Name Hospital; Institute For Clinical Research, Teaneck
Raleigh Neurology Associates, Raleigh
Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary
University of Alberta; Divison of Pulmonary Medicine, Dept. of Medicine,, Edmonton
Fraser Health Multiple Sclerosis Clinic; Burnaby Hospital Pharmacy, Burnaby
Horizon Health Network - Multiple Sclerosis Clinic, Saint John
Dalhousie Multiple Sclerosis Research Unit, Halifax
Hamilton General Hospital, Hamilton
The Ottawa Hospital - General Campus; Department of Neurology - Multiple Sclerosis, Ottawa
St. Michael's Hospital MS Clinic, MS Research Centre, Toronto
Clinique NeuroOutaouais, Gatineau
Recherche Sepmus, Inc., Greenfield Park
Hopital Hotel Dieu de Levis, Lévis
Chum Campus Notre Dame, Montreal
McGill University; Montreal Neurological Institute; Neurological and Psychiatric, Montreal
MS Clinic Mauricie Bois Francs, Trois-Rivières
CHU De Quebec Universite Laval, Québec
Lead Sponsor
Genentech, Inc.
INDUSTRY